Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:HURA NASDAQ:IMDX NYSEAMERICAN:SDEV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.23+0.9%$2.63$1.21▼$7.13$146.80M0.45340,218 shs62,297 shsHURATuHURA Biosciences$2.35-2.0%$2.08$0.41▼$4.20$150.60M-0.011.50 million shs94,363 shsIMDXOncocyte$4.72-4.0%$4.18$2.33▼$8.51$152.72M1.63212,029 shs18,183 shsSDEVStablecoin Development$1.85+12.1%$1.47$1.11▼$99.75$49.25M0.16419,974 shs55,941 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+5.24%-2.64%-3.91%-19.93%+60.14%HURATuHURA Biosciences+0.84%+3.00%+5.73%+98.35%-39.55%IMDXOncocyte-2.00%+17.46%+54.89%-33.74%+490,999,900.00%SDEVStablecoin Development+1.23%+25.95%+3.12%-52.86%-41.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.23+0.9%$2.63$1.21▼$7.13$146.80M0.45340,218 shs62,297 shsHURATuHURA Biosciences$2.35-2.0%$2.08$0.41▼$4.20$150.60M-0.011.50 million shs94,363 shsIMDXOncocyte$4.72-4.0%$4.18$2.33▼$8.51$152.72M1.63212,029 shs18,183 shsSDEVStablecoin Development$1.85+12.1%$1.47$1.11▼$99.75$49.25M0.16419,974 shs55,941 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+5.24%-2.64%-3.91%-19.93%+60.14%HURATuHURA Biosciences+0.84%+3.00%+5.73%+98.35%-39.55%IMDXOncocyte-2.00%+17.46%+54.89%-33.74%+490,999,900.00%SDEVStablecoin Development+1.23%+25.95%+3.12%-52.86%-41.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 2.00Hold$11.00393.27% UpsideHURATuHURA Biosciences 2.67Moderate Buy$9.00282.82% UpsideIMDXOncocyte 2.00Hold$12.00154.45% UpsideSDEVStablecoin Development 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SDEV, IMDX, HURA, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026HURATuHURA Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026HURATuHURA Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026HURATuHURA Biosciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/27/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/17/2026IMDXOncocyte Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AIMDXOncocyte$4.06M37.55N/AN/A($1.10) per share-4.29SDEVStablecoin Development$9.78M5.04N/AN/A($0.92) per share-2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$30.84M-$0.48N/AN/AN/AN/AN/A-214.23%5/21/2026 (Estimated)HURATuHURA Biosciences-$30.05M-$0.63N/AN/AN/AN/A-182.40%-117.49%5/15/2026 (Estimated)IMDXOncocyte-$50.22M-$1.62N/AN/AN/A-1,238.52%N/A-79.78%N/ASDEVStablecoin Development-$22.14M-$9.95N/AN/AN/AN/A-445.74%-453.46%N/ALatest SDEV, IMDX, HURA, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GALTGalectin Therapeutics-$0.06N/AN/AN/AN/AN/A5/15/2026N/AHURATuHURA Biosciences-$0.12N/AN/AN/AN/AN/A3/31/2026Q4 2025HURATuHURA Biosciences-$0.1233-$0.13-$0.0067-$0.10N/AN/A3/30/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 million3/19/2026Q4 2025SDEVStablecoin DevelopmentN/A-$7.60N/A-$7.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ASDEVStablecoin DevelopmentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A2.422.42HURATuHURA BiosciencesN/A0.780.78IMDXOncocyteN/A1.271.23SDEVStablecoin DevelopmentN/A7.607.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%HURATuHURA Biosciences0.62%IMDXOncocyte55.35%SDEVStablecoin Development23.25%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics52.60%HURATuHURA Biosciences0.20%IMDXOncocyte2.05%SDEVStablecoin Development43.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics965.83 million31.20 millionOptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/AIMDXOncocyte12032.29 million31.63 millionN/ASDEVStablecoin Development3026.62 million14.96 millionNot OptionableSDEV, IMDX, HURA, and GALT HeadlinesRecent News About These CompaniesCrypto News Today: Bitcoin Inflows, XRPL Unlocks and Ethereum Activity RisesApril 17, 2026 | analyticsinsight.netATether Backs $SKY Treasury Company in $134M Private SaleApril 17, 2026 | finance.yahoo.comTether Announces Participation in $134M SKY DAT Private PlacementApril 16, 2026 | finance.yahoo.comTether Backed a $134M SKY Crypto Token Deal: What It Says About Stablecoin PowerApril 16, 2026 | finance.yahoo.comTether Backs $134 Million Raise to Drive Stablecoin AdoptionApril 16, 2026 | cryptonewsz.comCTether Backs Stablecoin Infrastructure Push With $134 Million BetApril 16, 2026 | thecurrencyanalytics.comTTether Backs $134M Bet as Stablecoins Go Fully MainstreamApril 16, 2026 | livebitcoinnews.comLTether Backs $134 Million Funding Round for New Stablecoin InfrastructureApril 16, 2026 | news.bitcoin.comTether Invests in Stablecoin Firm, Stablecoin Development CorporationApril 15, 2026 | crowdfundinsider.comCTether Joins $134 Million SDEV Financing as Stablecoin Infrastructure ExpandsApril 15, 2026 | finance.yahoo.comStablecoin Development CorporationApril 8, 2026 | cnn.comStablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”April 8, 2026 | theglobeandmail.comStablecoin Development Corp (SDEV): Former NovaBay Completes $147M SKY Token Acquisition and Corporate RebrandMarch 25, 2026 | blockonomi.comNovaBay Pharmaceuticals (NBY) Soars 19% Following Stablecoin Transformation AnnouncementMarch 24, 2026 | blockonomi.comEyecare biotech jumps 19% after stablecoin-focused pivotMarch 24, 2026 | msn.comNovaBay rebrands to Stablecoin Development Corp in full crypto pivot—pharma company's stock climbs 19%March 24, 2026 | msn.comNovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%March 23, 2026 | benzinga.comNovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%March 23, 2026 | benzinga.comPharma company rebrands to Stablecoin Development Corp, drops $134M on SKY tokensMarch 23, 2026 | cryptobriefing.comCPharmaceutical Stock Jumps 26% on Crypto Pivot PlanMarch 23, 2026 | blockonomi.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDEV, IMDX, HURA, and GALT Company DescriptionsGalectin Therapeutics NASDAQ:GALT$2.23 +0.02 (+0.90%) As of 10:45 AM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.TuHURA Biosciences NASDAQ:HURA$2.35 -0.05 (-2.04%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Oncocyte NASDAQ:IMDX$4.72 -0.19 (-3.95%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Stablecoin Development NYSEAMERICAN:SDEV$1.85 +0.20 (+12.12%) As of 10:47 AM EasternStablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
